Importance of "targeted therapy" in EGFR-mutated Lung Cancer after Radiochemotherapy

被引：0
|
作者：
Mueller, Joerg Andreas [1 ,2 ]
Vordermark, Dirk [1 ]
机构：
[1] Univ Klin Halle Salle, Klin & Poliklin Strahlentherapie, Ernst Grube Str 40, D-06112 Halle, Saale, Germany
[2] Arbeitsgrp Junge DEGRO Deutsch Gesell Radioonkol e, Berlin, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2024年 / 200卷 / 10期
关键词：
CHEMORADIOTHERAPY; DURVALUMAB; NSCLC;
D O I：
10.1007/s00066-024-02284-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：921 / 923
页数：3
相关论文
共 50 条
  • [21] Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
    Shepherd, Annemarie F.
    Preeshagul, Isabel R.
    Shaverdian, Narek
    Wu, Abraham J.
    Gelblum, Daphna Y.
    Gomez, Daniel R.
    Rimner, Andreas
    Simone, Charles B., II
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
  • [22] Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib
    White, M.
    Neal, J. W.
    Gardner, R. M.
    Cunanan, K. M.
    Das, M.
    Padda, S. K.
    Ramchandran, K.
    Chen, T. T.
    Wakelee, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S773 - S774
  • [23] Factors affecting outcome in resected EGFR-mutated lung cancer
    Eide, Inger Johanne Zwicky
    Nilssen, Yngvar
    Lund-Iversen, Marius
    Brustugun, Odd Terje
    ACTA ONCOLOGICA, 2022, 61 (06) : 749 - 756
  • [24] OsimertinibAcquired resistance in EGFR-mutated lung cancer: case report
    Reactions Weekly, 2021, 1836 (1) : 619 - 619
  • [25] EGFR-mutated lung cancer in Li-Fraumeni syndrome
    Michalarea, Vasiliki
    Calcasola, Matthew
    Cane, Paul
    Tobal, Khalid
    Izatt, Louise
    Spicer, James
    LUNG CANCER, 2014, 85 (03) : 485 - 487
  • [26] RETRACTED: Cell membrane based biomimetic nanocomposites for targeted therapy of drug resistant EGFR-mutated lung cancer (Retracted Article)
    Wu, Pengying
    Yin, Dongtao
    Liu, Jiaming
    Zhou, Huige
    Guo, Mengyu
    Liu, Jing
    Liu, Yang
    Wang, Xiaobing
    Liu, Ying
    Chen, Chunying
    NANOSCALE, 2019, 11 (41) : 19520 - 19528
  • [27] Targeted NGS analysis to predict recurrence in resected EGFR-mutated lung adenocarcinoma
    Kim, In Ae
    Kim, Hee Jung
    Hur, Jae Young
    Lee, Seung En
    Park, Jung Hoon
    Lee, Song Am
    Hwang, Jae Jun
    Kim, Wan Seop
    Lee, Kye Young
    CANCER RESEARCH, 2020, 80 (16)
  • [28] Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 44 - 54
  • [29] Aumolertinib as adjuvant therapy in postoperative EGFR-mutated non-small cell lung cancer
    Zhang, Q.
    He, C.
    He, T.
    Wang, Y.
    Lv, W.
    Hu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S73 - S73
  • [30] Erlotinib as Maintenance Therapy Shows PFS Benefit for Lung Cancer Patients With EGFR-Mutated Tumors
    不详
    ONCOLOGY-NEW YORK, 2011, 25 (12): : 1239 - 1240
12345